Molecular Partners (MOLN) FY Conference Transcript

Summary of Molecular Partners Conference Call Company Overview - Company: Molecular Partners - Focus: Development of DARPins, small binding proteins for targeted therapies in oncology [4][5] Key Platforms and Pipeline - DARPins Platforms: - Radiotherapy DARPin Platform: Utilizes small size to deliver radioisotopes effectively [6] - T Cell Engager Platform: Capable of creating bispecific to tetraspecific DARPins targeting multiple tumor antigens [6] - Clinical Candidates: - MPO-712 (DLL3): Expected to enter Phase 1 trials in the second half of the year, targeting small cell lung cancer [12][15] - MPO-533: Involved in an ongoing Phase 1 trial for acute myeloid leukemia (AML) [44] DLL3 and Small Cell Lung Cancer - Target: DLL3, a marker for neuroendocrine tumors, particularly expressed in small cell lung cancer [15] - Clinical Need: High unmet medical need in small cell lung cancer, which is often chemo-resistant [15][13] - Phase 1 Trial: Aiming to start in the second half of the year, with a focus on relapsed refractory patients [16][19] Radioligand Therapy Insights - Advantages of DARPins: Selected for targets that are not easily ligandable, providing a solution for over 70% of targets [9][10] - Imaging and Dosimetry: Early imaging data expected to inform dosing and therapeutic windows, with results anticipated in H2 [19][20] - Lead-212: Chosen for its short half-life and effective energy delivery, partnered with OranoMed for supply [31][34] MPO-533 and AML Trial Adjustments - Targeting Strategy: Trispecific and tetraspecific DARPins designed to target multiple antigens on AML cells [46] - Trial Adjustments: Shifted to more frequent dosing to improve patient exposure and response rates, achieving a 30% complete response rate in recent evaluations [51][52] Future Developments - Switched DARPin Platform: Aiming to develop smart drugs that utilize logic gating to enhance T cell engagement [58][61] - Investor Interest: The new platform is generating interest from potential investors and pharmaceutical partners [62] Additional Considerations - Supply Chain Management: OranoMed's ability to provide a consistent supply of Lead-212 is crucial for the success of the radioligand therapy [39][41] - Regulatory Engagement: Ongoing constructive discussions with regulators to ensure effective clinical trial designs [29][42] This summary encapsulates the key points discussed during the conference call, highlighting Molecular Partners' innovative approaches in oncology and their strategic focus on DARPins and radioligand therapies.